Berotralstat

ORLADEYO ® is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 2 years of age and older.

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for: ORLADEYO ® is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 2 years of age and older.

Side effects, and when to stop

The following clinically significant adverse reaction is described elsewhere in the labeling:

QTc Interval Prolongation.

Who should not take it

None.

Storing it

Store at 20°C to 25°C (68°F to 77°F). Excursions permitted between 15°C and 30°C (59°F to 86°F).

Cite this page

NLM: sofidex [Internet]. Daloreum; c2026. Berotralstat; [reviewed 2026 Aug 2; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/berotralstat
APA 7th: sofidex. (2026, August 2). Berotralstat. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/berotralstat
AMA 11th: Berotralstat. sofidex. Reviewed August 2, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/berotralstat

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.